Aliases & Classifications for Withdrawal Disorder

MalaCards integrated aliases for Withdrawal Disorder:

Name: Withdrawal Disorder 12 14
Substance Withdrawal Syndrome 69
Withdrawal Syndrome 52

Classifications:



External Ids:

Disease Ontology 12 DOID:0060001

Summaries for Withdrawal Disorder

Disease Ontology : 12 A substance-related disorder that occurs upon the abrupt discontinuation/separation or a decrease in dosage of the intake of medications, recreational drugs, and alcohol.

MalaCards based summary : Withdrawal Disorder, also known as substance withdrawal syndrome, is related to barbiturate dependence and hole retinal cyst, and has symptoms including seizures, drug withdrawal symptoms and withdrawal symptoms. An important gene associated with Withdrawal Disorder is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Peptide ligand-binding receptors and G alpha (s) signalling events. The drugs Everolimus and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and prostate, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Withdrawal Disorder

Diseases related to Withdrawal Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 54)
id Related Disease Score Top Affiliating Genes
1 barbiturate dependence 11.0
2 hole retinal cyst 10.7 AR KLK3
3 endometriosis 10.7 AR KLK3
4 mucinous adenocarcinoma 10.7 AR KLK3
5 neonatal abstinence syndrome 10.7
6 cystic hygroma lethal cleft palate 10.7 CNR1 OPRM1
7 dementia - subcortical 10.6 CNR1 OPRM1
8 glioblastoma proneural subtype 10.6 AR KLK3
9 chronic tympanitis 10.6 OPRM1 PDYN
10 prostate small cell carcinoma 10.5 AR KLK3
11 cervicitis 10.5 FOS OPRM1
12 hyperimmunoglobulin syndrome 10.4 FOS HTR7
13 cutaneous adenocystic carcinoma 10.4 KLK3 POMC
14 bagassosis 10.4 KLK3 POMC
15 cholangiolocellular carcinoma 10.4 KLK3 POMC
16 eosinophilia-myalgia syndrome 10.3 OPRM1 PDYN
17 conjunctival pigmentation 10.3 CRH HTR7
18 adult mesenchymal chondrosarcoma 10.2 PDYN POMC
19 allergic hypersensitivity disease 10.2 CNR1 FOS HTR7
20 vascular cancer 10.2 CNR1 FOS HTR7
21 pfeiffer syndrome 10.2 POMC TSPO
22 rhabdoid cancer 10.2 PDYN POMC
23 hypertrophy of breast 10.1 HTR7 TSPO
24 capillary disease 10.1 AR KLK3 POMC
25 sphingolipidosis 10.1 AR POMC
26 intermittent squint 10.1 CRH POMC
27 renal pelvis carcinoma 10.1 CRH POMC
28 actinobacillosis 10.1 CRH POMC
29 ulcerative blepharitis 10.1 CRH POMC
30 hypodermyasis 10.0 CRH POMC
31 heroin dependence 10.0 CNR1 OPRM1 POMC
32 suppurative periapical periodontitis 10.0 OPRM1 PDYN POMC
33 febrile infection-related epilepsy syndrome 10.0 CRH POMC
34 esophagus sarcoma 10.0 AR KLK3
35 acute female pelvic peritonitis 10.0 OPRM1 PDYN POMC
36 dressler's syndrome 10.0 CRH POMC
37 early-onset parkinson disease 9.9 CRH POMC
38 traumatic glaucoma 9.9 CRH POMC
39 calcinosis 9.9 CRH KLK3 POMC
40 capillary lymphangioma 9.8 AR CRH POMC
41 may-hegglin anomaly 9.8 CRH POMC TSPO
42 trabecular follicular adenocarcinoma 9.8 CRH POMC
43 keratosis 9.7 CRH HTR7 POMC
44 uterine corpus adenocarcinofibroma 9.7 CRH POMC
45 pheochromocytoma 9.7 CRH FOS POMC
46 bronchiectasis 9.6 CRH POMC
47 transsexualism 9.5 CNR1 FOS HTR7 PDYN TSPO
48 pervasive developmental disorder 9.3 CNR1 HTR7 OPRM1 PDYN POMC
49 epileptic encephalopathy, early infantile, 45 9.3 CNR1 HTR7 OPRM1 PDYN POMC
50 hallucinogen dependence 9.2 CNR1 CRH OPRM1 PDYN POMC

Graphical network of the top 20 diseases related to Withdrawal Disorder:



Diseases related to Withdrawal Disorder

Symptoms & Phenotypes for Withdrawal Disorder

UMLS symptoms related to Withdrawal Disorder:


seizures, drug withdrawal symptoms, withdrawal symptoms, opiate withdrawal symptoms

MGI Mouse Phenotypes related to Withdrawal Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.16 AR CNR1 CRH FOS HTR7 JAG1
2 homeostasis/metabolism MP:0005376 10.06 AR CNR1 CRH FOS HTR7 JAG1
3 cellular MP:0005384 10.03 CNR1 CRH FOS JAG1 OPRM1 POMC
4 growth/size/body region MP:0005378 10.02 AR CNR1 CRH FOS JAG1 OPRM1
5 adipose tissue MP:0005375 9.95 CNR1 CRH OPRM1 PDYN POMC AR
6 endocrine/exocrine gland MP:0005379 9.95 AR CRH FOS JAG1 OPRM1 POMC
7 integument MP:0010771 9.91 CRH FOS HTR7 JAG1 OPRM1 PDYN
8 nervous system MP:0003631 9.81 AR CNR1 CRH FOS HTR7 JAG1
9 no phenotypic analysis MP:0003012 9.43 CNR1 CRH JAG1 OPRM1 PDYN POMC
10 normal MP:0002873 9.17 AR CNR1 CRH FOS JAG1 OPRM1

Drugs & Therapeutics for Withdrawal Disorder

Drugs for Withdrawal Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1206)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 159351-69-6 6442177
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 22916-47-8 4189
3
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 128794-94-5 5281078
4
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 24280-93-1 446541
5
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
6
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 53123-88-9 5284616 6436030 46835353
7
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 104987-11-3 445643 439492
8
Basiliximab Approved, Investigational Phase 4,Phase 2 152923-56-3, 179045-86-4
9
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
10
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
11
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2 185243-69-0
12
Bupropion Approved Phase 4,Phase 2,Phase 3,Phase 1 34841-39-9, 34911-55-2 444
13
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
14
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
15
Fluoxetine Approved, Vet_approved Phase 4,Phase 3 54910-89-3 3386
16
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
17
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
18
Milnacipran Approved Phase 4,Phase 3,Phase 2 92623-85-3 65833
19
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
20
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
21
Acamprosate Approved, Investigational Phase 4,Phase 2,Phase 3 77337-76-9 71158
22
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2 1959-05-2, 59-05-2 126941
23
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
24
Bisoprolol Approved Phase 4 66722-44-9 2405
25
Candesartan Approved Phase 4,Phase 3 139481-59-7 2541
26
Captopril Approved Phase 4 62571-86-2 44093
27
Carvedilol Approved, Investigational Phase 4,Phase 2 72956-09-3 2585
28
Enalapril Approved, Vet_approved Phase 4,Phase 2 75847-73-3 5362032 40466924
29
Enalaprilat Approved Phase 4,Phase 2 76420-72-9 6917719
30
Eplerenone Approved Phase 4,Phase 3 107724-20-9 150310 443872
31
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
32
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
33
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
34
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
35
Spironolactone Approved Phase 4,Phase 3 1952-01-7, 52-01-7 5833
36
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2 137862-53-4 60846
37
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
38
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-78-2 2244
39
Sodium oxybate Approved Phase 4 502-85-2 5360545
40
Clozapine Approved Phase 4,Phase 3 5786-21-0 2818
41
Haloperidol Approved Phase 4,Phase 3 52-86-8 3559
42
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
43
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1 2216-51-5 16666
44
Levobupivacaine Approved Phase 4 27262-47-1 92253
45
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52485-79-7 40400 644073
46
Heroin Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 561-27-3 5462328
47
Gliclazide Approved Phase 4 21187-98-4 3475
48
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
49
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 59467-70-8 4192
50
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 1 137-58-6 3676

Interventional clinical trials:

(show top 50) (show all 3163)

id Name Status NCT ID Phase Drugs
1 Efficacy of Certican® in Combination With Myfortic® in Renal Unknown status NCT01399242 Phase 4 Certican
2 Steroid Withdrawal Immunosuppression After Renal Transplantation Unknown status NCT01550445 Phase 4 Prednisolone
3 Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4 etanercept;etanercept
4 Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial Unknown status NCT00120978 Phase 4 Advair;Flovent
5 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
6 Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit Unknown status NCT02025855 Phase 4 Methadone;Placebo
7 Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4 Milnacipran;Placebo
8 Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain Unknown status NCT01264237 Phase 4 Etoricoxib;Placebo
9 Acamprosate vs. Placebo in Bipolar Alcoholics Unknown status NCT00466661 Phase 4 Acamprosate;Placebo
10 Remission Induction in Very Early Rheumatoid Arthritis Unknown status NCT00523692 Phase 4 Etanercept, methotrexate and depomedrone;depemedrone
11 Study to Evaluate the Efficacy and Safety of Aripiprazole Unknown status NCT02069977 Phase 4 Aripiprazole
12 Physiological Response to Heliox21 and Air O2 Unknown status NCT01498432 Phase 4 Heliox21;Air O2
13 Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients Unknown status NCT02200822 Phase 4 beta blockers;RAAS blockers
14 Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome Unknown status NCT01823770 Phase 4 Rotigotine;Placebo patchs
15 WHAT (Women, Hot-flashes, Activity, Trial) - Physical Activity for Treatment of Hot Flushes Among Postmenopausal Women Unknown status NCT01282320 Phase 4
16 GRK4 Polymorphisms Blood Pressure Response to Candesartan Unknown status NCT01629225 Phase 4 Candesartan
17 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
18 Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4 Sodium oxybate;Placebo
19 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4 aripiprazole
20 Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
21 A Dose Finding Study for Pain Relief of a Broken Hip Unknown status NCT00926666 Phase 4 Levobupivacaine
22 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches Unknown status NCT00750217 Phase 4 Buprenorphine patch and sublingual tablets
23 The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy Unknown status NCT00647322 Phase 4
24 Variation in Sulphonylurea Response in Type 2 Diabetes Unknown status NCT00738088 Phase 4 gliclazide
25 The Psychological Effects of Different Sedation Protocol on Mechanically Ventilated Critically Ill Adults. Unknown status NCT02123589 Phase 4 Deep sedation(midazolam and fentanyl );Deep and daily interruption of sedation(midazolam and fentanyl );Light sedation(midazolam and fentanyl )
26 Prophylactic Lidocaine Spray for Pain Alleviation in Women Undergoing Osmotic Dilator Insertion for Second Trimester Dilatation and Evacuation Unknown status NCT02097017 Phase 4 Lidocaine
27 Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU Unknown status NCT01962116 Phase 4 Citrate 4%;unfractionated heparin
28 BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study) Unknown status NCT02398929 Phase 4 Bisoprolol 2.5 mg;Placebo
29 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
30 VIP: Vascular Imaging Project. Study on the Progression of Cardiovascular Disease in Renal Transplant Recipients Completed NCT00169910 Phase 4 AUC monitored withdrawal of MMF or CNI
31 Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder Completed NCT01439126 Phase 4 clonidine hydrochloride;Placebo
32 Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder Completed NCT00877487 Phase 4 SPD489 (Lisdexamfetamine dimesylate);Placebo
33 Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease Completed NCT00975195 Phase 4 tiotropium inhalation;salmeterol xinafoate;fluticasone propionate;placebo matched for fluticasone propionate
34 Withdrawal of Inhaled Corticosteroids in Patients With COPD in Primary Care Completed NCT00440687 Phase 4 Fluticasone 500mcg BD via accuhaler or identical placebo
35 The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia Completed NCT00373126 Phase 4 transdermal nicotine patch
36 A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease Completed NCT01711866 Phase 4 Rotigotine
37 Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. Completed NCT00001730 Phase 4 Thyrogen
38 Magnesium After Alcohol Withdrawal Treatment Completed NCT00325299 Phase 4 Magnesium
39 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study Completed NCT02915354 Phase 4 Etanercept
40 Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA Completed NCT00792233 Phase 4
41 Withdrawal Versus Continuation of Amiodarone in Successfully Treated Patients With Persistent Atrial Fibrillation Completed NCT00845780 Phase 4 withdrawal or continuation of amiodarone therapy
42 Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment Completed NCT00489255 Phase 4 Tigan®;Placebo
43 Reducing Cardiovascular Disease by Combining Smoking Cessation Pharmacotherapy and Behavioural Counseling Completed NCT01623505 Phase 4 Champix;Transdermal Nicoderm patch combined with gum or inhaler;Transdermal Nicoderm patch
44 Tobacco Cessation in Postmenopausal Women (Part I) - 1 Completed NCT00061061 Phase 4
45 Dopaminergic Modulation of Declarative Memory Completed NCT03151460 Phase 4 Dopamine Agent
46 An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders Completed NCT01855074 Phase 4 Risperidone
47 Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder Completed NCT01010204 Phase 4 Varenicline (Chantix);Placebo
48 ESTEROID WITHDRAWAL STUDY, SAFETY AND EFFICACY IN RENAL TRANPLANTATION Completed NCT02328222 Phase 4 ESW group
49 An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment Completed NCT00526877 Phase 4 Risperidone
50 Buprenorphine in the Emergency Department Completed NCT03174067 Phase 4 Buprenorphine;Clonidine

Search NIH Clinical Center for Withdrawal Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Withdrawal Disorder

Anatomical Context for Withdrawal Disorder

MalaCards organs/tissues related to Withdrawal Disorder:

39
Lung, Kidney, Prostate, Liver, Brain, Thyroid, Heart

Publications for Withdrawal Disorder

Variations for Withdrawal Disorder

Expression for Withdrawal Disorder

Search GEO for disease gene expression data for Withdrawal Disorder.

Pathways for Withdrawal Disorder

GO Terms for Withdrawal Disorder

Biological processes related to Withdrawal Disorder according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.74 CNR1 FOS OPRM1
2 aging GO:0007568 9.71 CNR1 FOS TSPO
3 response to ethanol GO:0045471 9.61 CNR1 CRH OPRM1
4 negative regulation of blood pressure GO:0045776 9.56 CNR1 CRH
5 response to morphine GO:0043278 9.55 CNR1 OPRM1
6 response to immobilization stress GO:0035902 9.52 CRH FOS
7 response to pain GO:0048265 9.51 CRH TSPO
8 adrenal gland development GO:0030325 9.49 CRH TSPO
9 regulation of N-methyl-D-aspartate selective glutamate receptor activity GO:2000310 9.46 CRH OPRM1
10 chemical synaptic transmission GO:0007268 9.46 CRH HTR7 OPRM1 PDYN
11 neuropeptide signaling pathway GO:0007218 9.43 OPRM1 PDYN POMC
12 response to corticosterone GO:0051412 9.4 CRH FOS
13 sensory perception GO:0007600 9.37 OPRM1 PDYN
14 regulation of synaptic transmission, GABAergic GO:0032228 9.32 CNR1 NISCH
15 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.13 CNR1 HTR7 OPRM1
16 response to cocaine GO:0042220 8.8 CNR1 CRH OPRM1
17 signal transduction GO:0007165 10.02 AR CNR1 CRH HTR7 OPRM1 POMC

Molecular functions related to Withdrawal Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 androgen binding GO:0005497 8.96 AR TSPO
2 neuropeptide hormone activity GO:0005184 8.62 CRH PDYN

Sources for Withdrawal Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....